Angiotensin Receptor Blockers Decrease the Risk of Major Adverse Cardiovascular Events in Patients with End-Stage Renal Disease on Maintenance Dialysis: A Nationwide Matched-Cohort Study.
Major adverse cardiovascular events (MACE) cause the leading cause of morbidity and mortality in patients with end-stage renal disease (ESRD) on maintenance Hemodialysis (HD) or peritoneal dialysis (PD). Many randomized-controlled trials (RCTs) have proved that angiotensin receptor blockers (ARBs) c...
Main Authors: | Chung-Wei Yang, Nian-Sheng Tzeng, Yun-Ju Yin, Chien-Hsun Li, Hung-An Chen, Shih-Hsiang Chiu, Shinn-Ying Ho, Hui-Ling Huang |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4619342?pdf=render |
Similar Items
-
Angiotensin II receptor blocker usage and risk of major adverse cardiac events in ESRD
by: Yin, Yun-Ju, et al.
Published: (2015) -
Evaluation of Effectiveness of Angiotensin Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers and Beta Blockers in Long-term Dialysis Patients with Chronic Heart Failure
by: Zhi-ying Hung, et al.
Published: (2017) -
Comparisons of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with other Antihypertensive Agents on Chronic Dialysis Patients
by: Hui-Lin Hsiao, et al.
Published: (2011) -
Does a Supplemental Low-Protein Diet Decrease Mortality and Adverse Events After Commencing Dialysis? A Nationwide Cohort Study
by: Chieh-Li Yen, et al.
Published: (2018-08-01) -
Renal Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with Liver Cirrhosis: A Nationwide Cohort Study
by: Wei-Fan Hsu, et al.
Published: (2019-01-01)